The Edmond J. Safra Core Programs for PD Research

An Edmond J. Safra Core Program for PD Research
06/09/2011
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) announces The Edmond J. Safra Core Programs for PD Research, part of the annual Pipeline Programs seeking to develop new treatments and ultimately a cure for Parkinson’s disease (PD). The Edmond J. Safra Core Programs for PD Research is a series of three funding opportunities (Rapid Response Innovation Awards, Target Validation and Clinical Intervention Awards) that seek investigator-initiated proposals focused on the critical points along the translational pathway to new PD therapies.
To promote validation of novel targets, funding from our Target Validation program supports work demonstrating whether modulation of a novel biological target has impact in a PD-relevant animal model – an essential early step to the development of potential targeted therapies.
Please note that pre-proposals are mandatory for the Target Validation program and will be used to evaluate your proposal’s fit with the stated aims and review criteria of the RFA. All pre-proposals received in response to this program will be subjected to a triage process and only those pre-proposals deemed to be of suitable scientific merit will be invited to submit a full application.
Further program details, guidance about the types of proposals and focus areas of greatest interest to MJFF, and instructions for submission can be found in the RFA.
Please click on the links below for all submission information:
Initial Release Date: June 9, 2011
Conference Call*: March 21, 2012 – 12pm U.S. ET
Pre-Proposal Receipt Date: May 31, 2012 – 6pm U.S. ET
Full Application Invitation: June 20, 2012
Application Receipt Date: August 8, 2012 – 6:00pm U.S. ET
Anticipated Award Announcement: October 2012Anticipated Funding: November 2012
Note: The Target Validation program is launched approximately every six months. If you are unable to submit to the Spring 2012 funding cycle, the deadline for submission to the next cycle will be in June 2012.
MJFF employs an expedited, abbreviated granting mechanism to accelerate discoveries and ultimately translate findings to PD patients more quickly.
More